Pfizer, Ligand Win U.S. Approval for Hot Flash Therapy
This article is for subscribers only.
Pfizer Inc. and Ligand Pharmaceuticals Inc. won U.S. approval for a drug to treat hot flashes and osteoporosis.
The Food and Drug Administration cleared the drug, Duavee, for moderate-to-severe hot flashes related to menopause in women who haven’t had a hysterectomy, the agency said today in a statement. The medicine, also approved to prevent post-menopausal osteoporosis, will be available in the first quarter of 2014, Pfizer said today in a statement.